Form 8-K - Current report:
SEC Accession No. 0001628280-21-020378
Filing Date
2021-10-22
Accepted
2021-10-22 16:04:37
Documents
12
Period of Report
2021-10-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K sgmo-20211018.htm   iXBRL 8-K 40038
  Complete submission text file 0001628280-21-020378.txt   178597

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20211018.xsd EX-101.SCH 1941
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20211018_lab.xml EX-101.LAB 24132
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20211018_pre.xml EX-101.PRE 12545
5 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20211018_htm.xml XML 11634
Mailing Address 7000 MARINA BLVD BRISBANE CA 94005
Business Address 7000 MARINA BLVD BRISBANE CA 94005 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 211340572
SIC: 2836 Biological Products, (No Diagnostic Substances)